| 11/13/2025 15:30 |
Notice regarding the issuance of new shares as post-delivery restricted-stock-based remuneration |
| 11/07/2025 15:30 |
Notice Regarding the Recording of Non-Operating Expense (Foreign Exchange Loss) |
| 11/07/2025 15:30 |
Financial Results for the Nine Months Ended September 30, 2025 |
| 11/07/2025 15:30 |
Consolidated Financial Results for the Nine Months Ended September 30, 2025 [Japanese GAAP] |
| 10/01/2025 12:00 |
Notice Regarding Change of the Executive Officer |
| 08/14/2025 08:30 |
Modalis Receives Japanese Patent for DUX4 Gene-Targeted Therapy for Facioscapulohumeral Muscular Dystrophy |
| 08/07/2025 15:50 |
Business Plans and Matters Related to High Growth Potential |
| 08/07/2025 15:50 |
Business and Financial report for Six Months Ended June 30, 2025 |
| 08/07/2025 15:30 |
Notice Regarding the Recording of Non-Operating Expense (Foreign Exchange Loss) |
| 08/07/2025 15:30 |
Consolidated Financial Results for the Six Months Ended June 30, 2025 [Japanese GAAP] |
| 07/15/2025 15:30 |
Modalis Therapeutics to Present Epigenome Editing Technology and Preclinical Data at the 6th Annual Genome Editing Therapeutics Summit |
| 07/14/2025 15:30 |
Notice regarding the issuance of new shares as post-delivery restricted-stock-based remuneration |
| 07/11/2025 08:30 |
U.S. Patent Granted for Muscular Dystrophy Therapy Targeting LAMA1 |
| 07/08/2025 15:30 |
Modalis Therapeutics to Present MDL-101, a Muscle-Tropic AAV Vectors for the Treatment of LAMA2-CMD using CRISPR-GNDM epigenome editing technology |
| 07/07/2025 08:30 |
MODALIS Therapeutics and The Broad Institute Enter into License Agreement to Advance Therapies for LAMA2-Related Muscular Dystrophy |
| 07/01/2025 15:30 |
Notice regarding the Completion of the Pay-in Procedures for New Shares Issuance as post-delivery restricted-stock-based remuneration |
| 06/27/2025 15:30 |
Notice of Outlook for IND Filing of MDL-101 |
| 06/13/2025 15:30 |
Notice regarding the issuance of new shares as post-delivery restricted-stock-based remuneration |
| 06/11/2025 17:00 |
Modalis Therapeutics to participate in Nikkei Biotech Days conference |
| 05/30/2025 18:00 |
Notice regarding the Completion of the Pay-in Procedures for New Shares Issuance as post-delivery restricted-stock-based remuneration |
| 05/14/2025 15:30 |
Notice regarding the issuance of new shares as post-delivery restricted-stock-based remuneration |
| 05/13/2025 08:30 |
Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds |
| 05/08/2025 15:30 |
Notice Regarding the Recording of Non-Operating Expense (Foreign Exchange Loss) |
| 05/08/2025 15:30 |
Financial Results for the Three Months Ended March 31, 2025 |
| 05/08/2025 15:30 |
Consolidated Financial Results for the Three Months Ended March 31, 2025 [Japanese GAAP] |
| 04/30/2025 16:00 |
Notice regarding the Completion of the Pay-in Procedures for New Shares Issuance as post-delivery restricted-stock-based remuneration |
| 04/30/2025 09:00 |
Modalis to Present Preclinical Data on MDL-202 using CRISPR-GNDM epigenome editing technology at ASGCT 28th Annual Meeting |
| 04/23/2025 12:00 |
Modalis to Present MDL-202, a gene therapy for Myotonic Dystrophy Type 1 (DM1) using CRISPR-GNDM epigenome editing technology at 2025 MDF Conference |
| 04/14/2025 16:30 |
Notice Regarding Determination of Terms and Conditions of Stock Options (Share Acquisition Rights) |
| 04/14/2025 15:30 |
Notice regarding the issuance of new shares as post-issuance stock-based compensation |
| 03/27/2025 16:00 |
Notice Regarding Issuance of Stock Options (Share Acquisition Rights) |
| 03/27/2025 15:30 |
Business Plans and Matters Related to High Growth Potential |
| 03/05/2025 08:00 |
Notice of the 9th Ordinary General Meeting of Shareholders |
| 02/21/2025 15:30 |
Notice regarding changes in certified public accountants |
| 02/21/2025 15:30 |
Notice regarding partial amendment of the Articles of Incorporation |
| 02/21/2025 15:30 |
Announcement on Reduction in Amounts of Stated Capital and Capital Reserves and Appropriation of Other Capital Surplus |
| 02/13/2025 15:00 |
Notice Regarding the Variance between consolidated results and results of the previous year, non-consolidated results and results of the previous year |
| 02/13/2025 15:00 |
Notice Regarding the Recording of Non-Operating Income (Foreign Exchange Income) |
| 02/13/2025 15:00 |
2024 Fiscal Year End Business and Financial report |
| 02/13/2025 15:00 |
Consolidated Financial Results for the Fiscal Year Ended December 31, 2024 [Japanese GAAP] |
| 01/24/2025 08:30 |
LAMA2-CMD Patent Granted in Japan |
| 01/06/2025 12:00 |
JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy |
| 01/06/2025 08:30 |
Notice Regarding the Occurrence of an Incident of Electronic Fraud at a Subsidiary and the Recording of an Extraordinary Loss |
